Mallinckrodt PLC lost its bet to pay lower Medicaid rebates for Acthar Gel (repository corticotropin injection) by claiming the US Food and Drug Administration's approval of a new indication made it a new drug product.
In a 13 March ruling, a district court agreed with the US Centers for Medicare and Medicaid Services that Mallinckrodt and its subsidiary Questcor Pharmaceuticals Inc. have been miscalculating Acthar's Medicaid rebates since 2013
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?